Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients

doi:10.3748/wjg.v13.i20.2878

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 20

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2010)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-2) series.

Item

Count

PDF

196

HTML

1703

Tables (1-2)

111

Sum=2010

May 28, 2007 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. May 28, 2007; 13(20): 2878-2882
Published online May 28, 2007. doi: 10.3748/wjg.v13.i20.2878

Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients

Hai-Ying Lu, Li-Wei Zhuang, Yan-Yan Yu, Hadad Ivan, Chong-Wen Si, Zheng Zeng, Jun Li, Dong-Ming Hou, Xin-Yue Chen, Zhong-Hou Han, Yong Chen

Hai-Ying Lu, Li-Wei Zhuang, Yan-Yan Yu, Chong-Wen Si, Zheng Zeng, Jun Li, Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China

Hadad Ivan, Dong-Ming Hou, Indiana University School of Medicine, Indianapolis, IN 46202, United States

Xin-Yue Chen, Beijing You’an Hospital, Beijing 100054, China

Zhong-Hou Han, Qinhuangdao Third Hospital, Qinhuangdao 066000, Hebei Province, China

Yong Chen, Huai’an Infectious Disease Hospital, Huai’an 223300, Jiangsu Province, China

Author contributions: All authors contributed equally to the work.

Supported by Beijing Municipal Science & Technology Commission, No. H020920020690

Correspondence to: Professor Chong-Wen Si, Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China. bjsichongwen@sina.com

Telephone: +86-10-66551122-2370

Received: December 25, 2006
Revised: January 5, 2007
Accepted: January 14, 2007
Published online: May 28, 2007

Abstract

AIM: To evaluate the effect of antiviral agents on intrahepatic HBV DNA in HBeAg-positive chronic hepatitis B patients.

METHODS: Seventy-one patients received treatment with lamivudine, interferon alpha (IFN-α2b) or sequential therapy with lamivudine-IFN-α2b for 48 wk. All subjects were followed up for 24 wk. Serum and intrahepatic HBV DNA were measured quantitatively by PCR. HBV genotypes were analyzed by PCR-RFLP.

RESULTS: At the end of treatment, the intrahepatic HBV DNA level in 71 patients decreased from a mean of (6.1 ± 1.0) log10 to (4.9 ± 1.4) log10. Further, a larger decrease was seen in the intrahepatic HBV DNA level in patients with HBeAg seroconversion. Intrahepatic HBV DNA level (before and after treatment) was not significantly affected by the patients’ HBV genotype, or by the probability of virological flare after treatment.

CONCLUSION: Intrahepatic HBV DNA can be effectively lowered by antiviral agents and is a significant marker for monitoring antivirus treatment. Low intrahepatic HBV DNA level may achieve better efficacy of antivirus treatment.

Keywords: Intrahepatic HBV DNA, Histology, Antiviral therapy, HBV genotype